home All News open_in_new Full Article

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

CALGARY, Alberta, April 17, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces receipt of notification from the Nasdaq Stock Market LLC Listing Qualifications Department that […]


today 32 h. ago attach_file Economics

attach_file Other
attach_file Culture
attach_file Culture
attach_file Sport
attach_file Other
attach_file Other
attach_file Economics
attach_file Other
attach_file Other
attach_file Economics
attach_file Politics
attach_file Economics
attach_file Economics
attach_file Other
attach_file Other
attach_file Culture
attach_file Culture
attach_file Science
attach_file Other
attach_file Economics


ID: 1203393160
Add Watch Country

arrow_drop_down